Ventus Medical Limited

Ventus Medical Limited is a United Kingdom-based research and development company working at the intersection of medical devices and pharmaceuticals. According to its official website, the company is dedicated to creating safer nicotine delivery, with the stated mission of reducing tobacco harm and addressing what it describes as the single most preventable cause of premature death globally. The company positions itself as a specialist in novel inhalation technologies, bringing together expertise from the nicotine and pharmaceutical industries to create, develop and protect products intended to benefit public health. Ventus Medical's principal development is ENHALE, described on its website as a nicotine replacement therapy (NRT) inhaler. The company states that ENHALE is undergoing regulatory review in the United Kingdom and shortly within Europe, and characterises it as the first innovation in licensed medicine in over a decade. This regulatory pathway distinguishes Ventus Medical from many consumer nicotine product companies, as it is pursuing a licensed-medicine route rather than a general consumer goods route. The company describes itself as a medical device and pharmaceutical development company specialising in the innovation of novel inhalation technologies. Its stated goal is to address major public health challenges by realising safe and effective tools that policymakers can deploy to reduce morbidity and mortality and improve quality of life. Ventus Medical says it has developed an agile way of working, with dedicated specialists fostering an environment of quality and creativity, which it believes uniquely positions it to deliver ground-breaking technologies. Ventus Medical is headquartered in Liverpool, United Kingdom, according to Wikidata. Its leadership team includes founders Mark Dignum, who serves as Chief Technology Officer, and David Lawson, who serves as Chief Regulatory Officer. Both founders bring substantial experience from the nicotine and pharmaceutical sectors. Mark Dignum is a chemist by education who qualified as a European 'Qualified Person' and was responsible for establishing a world-class ENDS (electronic nicotine delivery systems) manufacturing site comprising 15 Grade D-GMP clean rooms and achieving GMP certification for the site at Nerudia. David Lawson, a biochemist by education, led the development of the world's first medically approved electronic cigarette, e-VOKE, and was responsible for establishing a world-class regulatory consultancy at Nerudia. He has completed an MBA at Alliance Manchester Business School. The company operates in the United Kingdom and is preparing for European market entry through the regulatory review of ENHALE. It is a private company. Ventus Medical aligns itself with the World Health Organization's belief that 'every person should be able to breathe tobacco-smoke-free air,' while emphasising that not all nicotine-containing products are created equally. It commits to exceeding regulatory requirements and being at the forefront of innovation and patient insights.

Ventus Medical Limited is a United Kingdom-based medical device and pharmaceutical development company headquartered in Liverpool. The company was founded by Mark Dignum and David Lawson, both of whom brought extensive experience from the nicotine and pharmaceutical industries to the venture. Mark Dignum, a chemist by education, qualified as a European 'Qualified Person' and built a career in the pharmaceutical industry. According to the company's website, he was responsible for establishing a world-class ENDS manufacturing site comprising 15 Grade D-GMP clean rooms and achieving GMP certification for the site at Nerudia. David Lawson, a biochemist by education, led the development of the world's first medically approved electronic cigarette, e-VOKE, and was responsible for establishing a world-class regulatory consultancy at Nerudia. He later completed an MBA at Alliance Manchester Business School. The founding of Ventus Medical reflects a broader trend in the nicotine and tobacco harm reduction sector, where experienced pharmaceutical and nicotine industry professionals have sought to develop regulated, medically licensed alternatives to combustible tobacco. Ventus Medical's stated mission is to create safer nicotine delivery through innovation and design, with the goal of aiding the decline of tobacco harm and potentially saving millions of lives. The company's principal development is ENHALE, a nicotine replacement therapy inhaler. According to the company's website, ENHALE is currently undergoing regulatory review in the United Kingdom and shortly within Europe, marking what the company describes as the first innovation in licensed medicine in over a decade. This regulatory review process is a significant milestone for the company, as obtaining a medicine licence would allow ENHALE to be marketed as a licensed nicotine replacement therapy rather than as a consumer product. Ventus Medical describes itself as a medical device and pharmaceutical development company specialising in the innovation of novel inhalation technologies. The company states that it brings together the expertise needed to create, develop and protect products that have the potential to significantly benefit public health. Its primary goal is to address the greatest public health challenges by realising safe and effective tools that can be deployed by policymakers to reduce morbidity and mortality and improve the quality of life of the general population. The company has developed an agile way of working, with dedicated specialists fostering an environment of quality and creativity. Ventus Medical states that it is uniquely positioned to deliver ground-breaking technologies. It aligns itself with the World Health Organization's belief that 'every person should be able to breathe tobacco-smoke-free air,' while emphasising that not all nicotine-containing products are created equally. The company commits to exceeding regulatory requirements and being at the forefront of innovation and patient insights. As of the available evidence, Ventus Medical operates primarily in the United Kingdom, with plans to expand into Europe through the regulatory review of ENHALE. The company is privately held. Its headquarters is in Liverpool, United Kingdom.

• Ventus Medical Limited is founded by Mark Dignum and David Lawson.

• ENHALE nicotine replacement therapy inhaler enters regulatory review in the United Kingdom.

• Ventus Medical prepares for regulatory review of ENHALE within Europe.

A research and development company developing safe and effective nicotine delivery through novel inhalation technologies, pursuing licensed-medicine regulatory pathways to support tobacco harm reduction.

• ENHALE

  A nicotine replacement therapy inhaler, described as the company's principal development and the first innovation in licensed medicine in over a decade. It is undergoing regulatory review in the UK and shortly within Europe.

1. 1NRT Inhaler | Nicotine Replacement Therapy | Ventus Medicalventusmedical.com
2. 2About | Ventus Medicalventusmedical.com
3. 3Ventus Medical Limited (United Kingdom) - Wikidatawikidata.org